La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
95 hedge funds and large institutions have $891M invested in La Jolla Pharmaceutical Company in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 19 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 26
2% more capital invested
Capital invested by funds: $871M → $891M (+$20.6M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
5% less funds holding
Funds holding: 100 → 95 (-5)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
60% less call options, than puts
Call options by funds: $2.17M | Put options by funds: $5.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$61.9M |
| 2 |
BlackRock
New York
|
+$8.92M |
| 3 |
RI
RTW Investments
New York
|
+$6.89M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.71M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$7.97M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.74M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$7.49M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$5.51M |
| 5 |
BC
Broadfin Capital
New York
|
-$5.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JGC
101
J. Goldman & Co
New York
| – | -$1.65M | -55,300 | Closed |
|
|
AI
102
Axiom Investors
Greenwich,
Connecticut
| – | -$1.23M | -41,310 | Closed |
|
|
HT
103
HAP Trading
New York
| – | -$1.09M | -36,636 | Closed |
|
|
PCM
104
Prelude Capital Management
New York
| – | -$1.05M | -33,956 | Closed |
|
|
PPA
105
Parametric Portfolio Associates
Seattle,
Washington
| – | -$490K | -16,467 | Closed |
|
106
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$447K | -15,000 | Closed |
|
|
AAM
107
Advisors Asset Management
Monument,
Colorado
| – | -$425K | -13,698 | Closed |
|
|
TRCT
108
Tower Research Capital (TRC)
New York
| – | -$382K | -12,833 | Closed |
|
|
JCM
109
Jafra Capital Management
New York
| – | -$358K | -12,018 | Closed |
|
110
Simplex Trading
Chicago,
Illinois
| – | -$359K | -11,638 | Closed |
|
|
WG
111
Winton Group
London,
United Kingdom
| – | -$276K | -9,259 | Closed |
|
|
PG
112
PEAK6 Group
Chicago,
Illinois
| – | -$173K | -5,800 | Closed |
|
113
SG Americas Securities
New York
| – | -$134K | -4,513 | Closed |
|
114
SEI Investments
Oaks,
Pennsylvania
| – | -$30.8K | -999 | -100% |
|
LJPC Hedge Fund Activity: Q2 2018 in Review
95 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2018, worth a combined $891M — up 2.4% from $871M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LJPC and 14 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 39 added.
The largest buyer was Scopia Capital Management, adding an estimated $61.9M. The largest seller was Boxer Capital, exiting entirely with an estimated $7.97M sold.
- 95 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2018, down from 100 in Q1 2018.
- Funds reported $891M of La Jolla Pharmaceutical Company stock for Q2 2018, up 2.4% quarter-over-quarter.
- 14 funds opened new La Jolla Pharmaceutical Company positions in Q2 2018 and 19 closed out, a net change of -5 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2018 was Scopia Capital Management, an estimated $61.9M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2018 was Boxer Capital, an estimated $7.97M sold.
Based on aggregated 13F filings for Q2 2018.